


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
MESO
Mesoblast Limited
$17.71
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
MESO Price Performance
$15.09 (+17.36%)
$17.01 (+4.12%)
$16.98 (+4.30%)
$17.53 (+1.03%)
MESO has High risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Low volume

MESO overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MESO Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
MESO Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is MESO current stock price?
What are MESO stock strengths?
What is MESO Risk Level?
What is MESO market cap and volume?
What is MESO current Stock IQ?
Should I buy MESO stock right now?
Is MESO a Strong Buy right now?
What does a 'Strong Buy' rating mean for MESO?
What does a 'Strong Sell' rating mean for MESO?
What factors influence MESO's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
MESO
Mesoblast Limited
Current Price
$17.71
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

MESO Price Performance
$15.09 (+17.36%)
$17.01 (+4.12%)
$16.98 (+4.30%)
$17.53 (+1.03%)
MESO Analysts Opinion
MESO Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MESO Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
MESO Street Sentiment is extremely bullish and have positive views on the near-term outlook
MESO has High risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Low volume

Average key support and resistance price levels
MESO Stock IQ
MESO Latest Analysis
Mesoblast (MESO) Sees Optimism From Analysts. We recently published 7 Best ASX Stocks to Buy Right Now. Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks. Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases heart failure and other ailments. On November 25th Jefferies upgraded the firms shares to Buy from Hold and increased the share price [….]
Today
Jefferies Upgrades Mesoblast Limited - Depositary Receipt (MESO). Fintel reports that on November 25 2025 Jefferies upgraded their outlook for Mesoblast Limited - Depositary Receipt (NasdaqGS:MESO) from Hold to Buy. Analyst Price Forecast Suggests 1.36% Upside
Wed Nov 26, 2025
Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies | DelveInsight. Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25 Key Companies |. DelveInsightChronic heart failure (CHF) is a progressive condition where the heart is unable to pump blood effectively leading to significant morbidity and healthcare burden. The growing elderly population inherently at higher risk for CHF is a major driver
Tue Nov 25, 2025
Mesoblast Sees Continued Ryoncil Revenue Growth For Q4 2025 . (RTTNews) - Mesoblast Limited (MESO) a biotechnology company developing allogeneic cellular medicines for inflammatory diseases sees continued strong growth in Ryoncil revenue for the fourth quarter ending December 31 2025.
Tue Nov 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MESO Stock trends
MESO Stock performance
MESO Stock analysis
MESO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.